Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa label

besponsa label

Перейти к контенту

Главное меню:

besponsa label
Welcome to BESPONSA® | BESPONSA®, Reference ID: 4140675 - Food and Drug Administration, Inotuzumab ozogamicin - Wikipedia, Package leaflet: Information for the user BESPONSA 1 mg , BESPONSA 1 mg powder for concentrate for solution for , Besponsa - Wyeth Pharmaceuticals LLC, a Subsidiary of , , , .
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. 9 /L. a . 50 × 10. 9 /L. a. Discontinue BESPONSA if low platelet count persists for greater than 28 days and is suspected to be related to BESPONSA. If prior to BESPONSA treatment.
Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). [1] [2] The medication consists of the humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.. BESPONSA is used to treat adults with acute lymphoblastic leukaemia. Acute lymphoblastic Acute lymphoblastic leukaemia is a cancer of blood where you have too many white blood cells.. The safety and efficacy of BESPONSA were evaluated in a single-arm, open-label, multicentre Phase 1/2 study (Study 2). Eligible patients were ≥ 18 years of age with relapsed or refractory B-cell precursor ALL.. Page 5: Wyeth Pharmaceuticals LLC, a Subsidiary of Pfizer Inc.: BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor. . .
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню